HiJAKing Immunotherapy-Resistant Melanoma for a Cure-Reference-Cited by-同舟云学术

HiJAKing Immunotherapy-Resistant Melanoma for a Cure

Published:2023-01-14 Issue:3 Volume:28 Page:196-198
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Shi Lewis Zhichang¹²³⁴⁵^ORCID,Shen Hongxing¹,Ojo Oluwagbemiga A¹,Bonner James A¹²^ORCID

Affiliation:

1. Department of Radiation Oncology, Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM) , Birmingham, AL , USA

2. O’Neal Comprehensive Cancer Center, University of Alabama School of Medicine , Birmingham, AL , USA

3. Department of Microbiology, University of Alabama School of Medicine , Birmingham, AL , USA

4. Department of Pharmacology and Toxicology, University of Alabama School of Medicine , Birmingham, AL , USA

5. Programs in Immunology, University of Alabama School of Medicine , Birmingham, AL , USA

Abstract

AbstractImmune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients.

Funder

American Cancer Society

Cancer Research Institute

Congressionally Directed Medical Research Programs

Siemens Healthineers

NIH

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/article-pdf/28/3/196/49806780/oyac270.pdf

Reference20 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Pd-1 and ctla-4 combination blockade expands infiltrating T cells and reduces regulatory t and myeloid cells within b16 melanoma tumors;Curran;Proc Natl Acad Sci USA,2010

3. Principles and use of anti-ctla4 antibody in human cancer immunotherapy;Peggs;Curr Opin Immunol,2006

4. Interdependent il-7 and ifn-gamma signalling in t-cell controls tumour eradication by combined alpha-ctla-4+alpha-pd-1 therapy;Shi;Nat Commun,2016

5. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies;Shen;Genes & Diseases.,2019